Background/Aims: Salicylate and chlorpromazine exert differential effects on the chemokine release from mast cells. Since these drugs are amphiphilic and preferentially partitioned into the lipid bilayers of the plasma membranes, they would induce some morphological changes in mast cells and thus affect the process of exocytosis. Methods: Employing the standard patch-clamp whole-cell recording technique, we examined the effects of salicylate and chlorpromazine on the membrane capacitance (Cm) during exocytosis in rat peritoneal mast cells. Using confocal imaging of a water-soluble fluorescent dye, lucifer yellow, we also examined their effects on plasma membrane deformation of the cells. Results: Salicylate dramatically accelerated the GTP-γ-S-induced increase in the Cm immediately after its application, whereas chlorpromazine significantly suppressed the increase. Treatment with salicylate increased the trapping of the dye on the cell surface, while treatment with chlorpromazine completely washed it out, indicating that both drugs induced membrane surface deformation in mast cells. Conclusion: This study demonstrated for the first time that membrane amphipaths, such as salicylate and chlorpromazine, may oppositely modulate the process of exocytosis in mast cells, as detected by the changes in the Cm. The plasma membrane deformation induced by the drugs was thought to be responsible for their differential effects.

No abstract

No abstract

Background Pancreatic serous cystic neoplasm (SCN) is an uncommon exocrine neoplasm, which is believed to be a benign entity. However, some of these neoplasms may occasionally attain metastatic ability. Von Hippel–Lindau disease (VHL) manifests a dominantly inherited systemic syndrome accompanied by several benign or malignant tumors, including cystic tumors, in various organs. We describe here a long-term survival case who underwent surgical resection for metachronous liver metastases of pancreatic SCN associated with VHL disease. Case presentation A 35-year-old woman with VHL underwent total pancreatectomy and right nephrectomy for pancreatic SCN and renal cell carcinoma, respectively. At the 4th year follow-up examination after the resection, contrast-enhanced computed tomography (CT) and gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) showed arterially hyper-enhanced neoplastic lesions in the segment VI and VIII of the liver. Partial resections of the liver were performed 53 months after the initial surgery. At the 6th month follow-up examination from the second surgery, one and two tumors located in the liver segment III, and VIII, respectively, were detected by contrast-enhanced CT and Gd-EOB-DTPA-enhanced MRI. Anterior segmentectomy and partial resection of the segment III were performed 66 months after the initial surgery and 13 months after the second, respectively. The tumors were pathologically diagnosed as liver metastases of pancreatic SCN synonymous with serous cystadenocarcinoma. She remains disease-free without recurrence 6.5 years after the last operation. Conclusions This is the first report of a case of metastatic SCN associated with VHL. Surgical resection might confer a favorable prognosis in patients of pancreatic SCN with liver metastases.

Objective is to assess the long-term oncological outcomes of LPDE performed in patients with pancreatic head and ampullary carcinoma Methods: 250 patients underwent LPDE during 2007-2018 years. 216 patients had malignancies (125 had pancreatic cancer, 44 patients had ampullary carcinoma) and 34 had benign diseases. Patients were followed up by control examination and phone calls every year. Kaplan-Maier survival analysis was performed in order to analyze long term results of treatment. Results: 119 patients with PDAC and 44 patients with ampullary carcinoma were followed up. 114 patients with PDAC were referred to adjuvant. Only 63 patients received chemotherapy, 26 patients had no chemotherapy and data about 25 patients was not available. Median overall survival rate (OSR) of patients with PDAC was 21 months. 5years OSR was 24%. Patient who did not receive adjuvant had significantly worse results with median OSR of 16 months vs 24 months. 5-years OSR of patients received chemo was significantly higher (27% vs 17%, p< 0.05). Another predictor of better survival was lymph nodes negativity, N+ patients had lower median OSR (26 months vs 18 months, p< 0.05) and 5-years OSR (27% vs 15%, p< 0.05). Patients with ampullary carcinoma had better oncological outcomes. Median OSR was 44 months and 5-years OSR was 52%. Conclusion: Lymph nodes positivity and non-receiving of adjuvant chemotherapy are predictors of lower survival rates in patients with pancreatic adenocarcinoma.